Notice for palovarotene (Ipsen Pty Ltd)
Active ingredients
palovarotene
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Capsule with hard shell
Indication
For the prevention of heterotopic ossification in patients with fibrodysplasia (myositis) ossificans progressiva (FOP)
Therapeutic area
Musculoskeletal